Osteoarthritis Injectables

Global Osteoarthritis Injectables Market to Reach US$9.7 Billion by 2030

The global market for Osteoarthritis Injectables estimated at US$6.6 Billion in the year 2024, is expected to reach US$9.7 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Hyaluronic Acid Injections, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Corticosteroid Injections segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 9.4% CAGR

The Osteoarthritis Injectables market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$651.0 Million by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Global Osteoarthritis Injectables Market – Key Trends & Drivers Summarized

How Are Osteoarthritis Injectables Transforming Pain Management and Joint Care?

The osteoarthritis injectables market has gained significant traction as non-surgical treatment options for managing joint pain and inflammation become increasingly preferred. With osteoarthritis (OA) affecting millions worldwide, patients and healthcare providers are seeking minimally invasive solutions to delay or avoid joint replacement surgery. Injectable therapies, including corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell-based treatments, are being widely adopted due to their ability to provide targeted pain relief, improve joint mobility, and enhance cartilage health. The aging global population and rising obesity rates—two major risk factors for OA—are further fueling the demand for effective injectables that offer prolonged relief without the side effects associated with oral pain medications.

What Role Do Emerging Biologic and Regenerative Therapies Play in Osteoarthritis Treatment?

The landscape of osteoarthritis treatment is shifting with the increasing adoption of biologic injectables and regenerative medicine approaches. PRP therapy, which utilizes the patient`s own blood-derived growth factors, has gained popularity as a promising alternative to traditional steroid injections. Stem cell-based therapies are also emerging, offering the potential for cartilage regeneration and long-term disease modification rather than just symptomatic relief. Additionally, advancements in hyaluronic acid formulations, including cross-linked and combination therapies, are improving the durability and efficacy of viscosupplementation. Research into gene therapy and monoclonal antibodies targeting inflammatory pathways is also underway, promising next-generation injectable treatments that could revolutionize OA management.

What Are the Key Challenges Limiting the Adoption of Osteoarthritis Injectables?

Despite their effectiveness, several barriers exist in the widespread adoption of osteoarthritis injectables. High treatment costs, particularly for biologic and stem cell-based therapies, remain a significant concern, limiting accessibility for many patients. Additionally, variability in clinical outcomes and the lack of standardized protocols for emerging regenerative treatments pose challenges for regulatory approval and physician adoption. Some injectable therapies, such as corticosteroids, have been associated with potential side effects, including cartilage degradation with prolonged use, leading to cautious prescribing practices. However, ongoing research and clinical trials are working to address these limitations, refining formulations and optimizing dosing regimens to enhance treatment efficacy and safety.

What’s Fueling the Growth of the Osteoarthritis Injectables Market?

The growth in the osteoarthritis injectables market is driven by several factors, including the increasing prevalence of osteoarthritis, rising demand for minimally invasive treatments, and advancements in biologic and regenerative therapies. The growing preference for outpatient and in-office procedures has boosted the adoption of injectable therapies over surgical interventions. Additionally, the expansion of reimbursement policies covering hyaluronic acid and PRP injections in various countries is supporting market growth. The rising geriatric population, along with increasing investments in R&D for novel osteoarthritis therapeutics, is further accelerating market expansion. The emergence of next-generation

SCOPE OF STUDY:

The report analyzes the Osteoarthritis Injectables market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Injection Type (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet-Rich Plasma (PRP) Injections, Other Injection Types); Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Other Anatomies); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 56 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Anika Therapeutics, Inc.
• Arthrex, Inc.
• Bayer AG
• Bioventus LLC
• Boehringer Ingelheim International GmbH
• Ferring Pharmaceuticals Inc.
• Fidia Farmaceutici S.p.A.
• Flexion Therapeutics, Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sanofi S.A.
• Seikagaku Corporation
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more